XML 27 R15.htm IDEA: XBRL DOCUMENT
v3.25.2

Stock-based Payments | 12 Months Ended
--- | ---
Apr. 30, 2025
Share-Based Payment Arrangement [Abstract] |
Stock-based Payments | Stock-based Payments Stock-based compensation in the amount of $654,000 and $1.1 million was recognized for years ended April 30, 2025 and 2024, respectively. Stock-based compensation costs were recorded as follows (in thousands):
| Year Ended April 30,
| 2025 |  | 2024
General and administrative | $ | 414 |  |  | $ | 706 |
Sales and marketing | 125 |  |  | 168 |
Research and development | 10 |  |  | 21 |
TOS cost of sales | 105 |  |  | 223 |
Total stock-based compensation expense | $ | 654 |  |  | $ | 1,118 |
The Company has in place a 2021 Equity Incentive Plan and 2010 Equity Incentive Plan ("the Plans"). In general, these Plans provide for stock-based compensation to the Company’s employees, directors and non-employees. The Plans also provide for limits on the aggregate number of shares that may be granted, the term of grants and the strike price of option awards. 2021 Equity Incentive Plan As part of the 2021 Annual Shareholders Meeting, shareholders approved the adoption of the 2021 Equity Incentive Plan (“2021 Equity Plan”). The purpose of the 2021 Equity Plan is to grant (i) Non-statutory Stock Options; (ii) Incentive Stock Options; (iii) Restricted Stock Awards; and/or (iv) Stock Appreciation Rights (collectively, stock-based compensation) to its employees, directors and non-employees. Total stock awards under the 2021 Equity Plan shall not exceed 2 million shares of common stock. Options and Stock Appreciation Rights expire no later than ten years from the date of grant and the awards vest as determined by the Board of Directors (the "Board") or Chief Executive Officer. Options and Stock Appreciation Rights have a strike price not less than 100% of the fair market value of the common stock subject to the option or right at the date of grant. As of April 30, 2025, approximately 1.2 million shares were left to issue under this plan. 2010 Equity Incentive Plan On February 18, 2011, shareholders owning a majority of the issued and outstanding shares of the Company executed a written consent approving the 2010 Equity Incentive Plan (“2010 Equity Plan”). The purpose of the 2010 Equity Plan is to grant (i) Non-statutory Stock Options; (ii) Restricted Stock Awards; and (iii) Stock Appreciation Rights (collectively, stock-based compensation) to its employees, directors and non-employees. Total stock awards under the 2010 Equity Plan shall not exceed 30,000,000 shares of common stock. Options and Stock Appreciation Rights expire no later than ten years from the date of grant and the awards vest as determined by the Board. Options and Stock Appreciation Rights have a strike price not less than 100% of the fair market value of the common stock subject to the option or right at the date of grant. After February 2021, no more shares were available to be issued from this plan. Director Compensation Plan On December 12, 2013, the Compensation Committee of the Board (the "Committee") adopted changes to the Director Compensation Plan of 2010 (the “Director Plan”) effective December 1, 2013. Under the Director Plan, independent directors of the Company were entitled to an annual award of a five-year option to purchase 8,333 shares of the Company’s common stock, and the Chairman of the Board of the Company was entitled to an annual award of a five-year option to purchase 16,667 shares of the Company’s common stock. Independent directors who serve as chairperson of a committee were also to receive an annual grant of a five-year option to purchase 1,667 shares of the Company’s common stock. During fiscal year 2021, the Committee adopted the Director Compensation Plan of 2021 (the "2021 Plan"). Under the 2021 Plan, independent directors are entitled to an annual base compensation of $100,000 which can be received in either ten-year options to purchase shares of the Company's stock, which vest fully over a one-year period, or a combination of options and cash, where cash received is not to exceed $35,000. The Chairman of the Board’s annual compensation was set at an equivalent of $150,000. Compensation for independent directors who serve as chairperson of a committee was set at an equivalent of between $110,000 to $120,000. All options issued under the 2021 Plan vest quarterly at a rate of 25%. Option grants will typically be issued after the annual shareholder meeting which will generally be held in October of each year. New directors will receive compensation upon joining the Board equal to a pro-rata equivalent for the remainder of the year. Options issued under the 2021 Plan are issued pursuant to the 2021 Equity Plan. Stock Option Grants Black-Scholes weighted average assumptions used to calculate the fair value of options granted during the years ended April 30, 2025 and 2024 were as follows:
| Year Ended April 30,
| 2025 |  | 2024
Expected term in years | 6 |  | 6
Risk-free interest rates | 3.6% - 4.5% |  | 4.0% - 4.5%
Volatility | 54% - 63% |  | 63% - 64%
Dividend yield | 0% |  | 0%
The weighted average fair value of stock options granted during the years ended April 30, 2025 and 2024, was $2.86 and $3.75, respectively. The Company’s stock options activity and related information as of and for the years ended April 30, 2025 and 2024 is as follows:
| Directors and Employees |  | Non- Employees |  | Total |  | Weighted Average Exercise Price |  | Weighted Average Remaining Contractual Life (Years) |  | Aggregate Intrinsic Value
Outstanding, May 1, 2024 | 1,883,166 |  |  | 36,331 |  |  | 1,919,497 |  |  | $ | 5.04 |  |  | 5.2 |  | $ | 2,172,000 |
Granted | 330,955 |  |  | — |  |  | 330,955 |  |  | 5.01 |  |  | 9.6 |  | $ | — |
Exercised | (183,404) |  |  | — |  |  | (183,404) |  |  | 3.64 |  |  |  |  |
Canceled | (83,325) |  |  | — |  |  | (83,325) |  |  | 5.83 |  |  |  |  |
Forfeited | (268,375) |  |  | — |  |  | (268,375) |  |  | 6.05 |  |  |  |  |
Expired | (36,666) |  |  | — |  |  | (36,666) |  |  | 5.43 |  |  |  |  |
Outstanding, April 30, 2025 | 1,642,351 |  |  | 36,331 |  |  | 1,678,682 |  |  | 4.98 |  |  | 4.9 |  | $ | 4,434,000 |
Vested and expected to vest as of April 30, 2025 | 1,642,351 |  |  | 36,331 |  |  | 1,678,682 |  |  | 4.98 |  |  | 4.9 |  | $ | 4,434,000 |
Exercisable as of April 30, 2025 | 1,461,067 |  |  | 5,625 |  |  | 1,466,692 |  |  | 4.86 |  |  | 4.3 |  | $ | 4,096,000 |
| Directors and Employees |  | Non- Employees |  | Total |  | Weighted Average Exercise Price |  | Weighted Average Remaining Contractual Life (Years) |  | Aggregate Intrinsic Value
Outstanding, May 1, 2023 | 1,739,336 |  |  | 36,331 |  |  | 1,775,667 |  |  | 4.8 |  | 4.6 |  | $ | 2,683,000 |
Granted | 444,730 |  |  | — |  |  | 444,730 |  |  | 6.08 |  |  | 9.5 |  | — |
Exercised | (155,449) |  |  | — |  |  | (155,449) |  |  | 2.31 |  |  |  |  |
Canceled | (50,535) |  |  | — |  |  | (50,535) |  |  | 4.82 |  |  |  |  |
Forfeited | (40,750) |  |  | — |  |  | (40,750) |  |  | 6.21 |  |  |  |  |
Expired | (54,166) |  |  | — |  |  | (54,166) |  |  | 12.78 |  |  |  |  |
Outstanding, April 30, 2024 | 1,883,166 |  |  | 36,331 |  |  | 1,919,497 |  |  | 5.04 |  |  | 5.2 |  | $ | 2,172,000 |
Vested and expected to vest as of April 30, 2024 | 1,883,166 |  |  | 36,331 |  |  | 1,919,497 |  |  | 5.04 |  |  | 5.2 |  | $ | 2,172,000 |
Exercisable as of April 30, 2024 | 1,481,145 |  |  | 3,750 |  |  | 1,484,895 |  |  | 4.65 |  |  | 4.2 |  | $ | 2,172,000 |
Share Repurchase Program On March 29, 2023, the Board of Directors approved a share repurchase program authorizing the Company to purchase up to an aggregate of $5.0 million of the Company’s common stock. The share repurchase program is designed in accordance with Rule 10b-18 of the Exchange Act. The shares may be purchased from time to time in the open market, as permitted under applicable rules and regulations, at prevailing market prices. The timing and amount of repurchases will depend on market conditions, share price, applicable legal requirements and other factors. The program does not obligate the Company to acquire a minimum number of shares. As of April 30, 2025, the Company had purchased approximately 120,300 shares of its common stock, at an average price of $5.73 per share, totaling approximately $708,000 and leaving an available balance of approximately $4.3 million authorized by the Board for use in the program as of that date. The Company did not purchase any shares of its common stock during the year ended April 30, 2025.

X
- Definition The entire disclosure for share-based payment arrangement. + References Reference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/718/tableOfContent Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (l) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details
Name: | us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration